White matter

NYU Langone Neurologists Present Latest Clinical Findings & Research at AAN 2024

Retrieved on: 
Saturday, April 13, 2024
Neuroimaging, American Academy, Brain, MCI, Stroke, White matter, Risk, Professor, News, NYU Langone Health, Doctor of Philosophy, Research, Appreciation, NYU, Deficit spending, Patient, AAN, Neurosurgery, Headache, Prevalence, MRI, Job satisfaction, Faculty, DSM-IV codes, Philip, Traumatic brain injury, Migraine, Practice, Biomarker, Annual general meeting, Organization, Growth, Medical imaging

DENVER, April 13, 2024 /PRNewswire/ -- Experts from NYU Langone's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology (AAN) 2024 Annual Meeting, April 13 to 18, in Denver.

Key Points: 
  • DENVER, April 13, 2024 /PRNewswire/ -- Experts from NYU Langone's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology (AAN) 2024 Annual Meeting, April 13 to 18, in Denver.
  • U.S. News & World Report's "Best Hospitals" ranks NYU Langone the No.
  • Researchers at NYU Langone surveyed 90 clinicians, residents, and fellows to identify the best methods of showing neurologists that they are valued in order to improve their job satisfaction and reduce burnout.
  • Further research is warranted to validate these findings and their potential to enhance early detection and intervention strategies for Alzheimer's disease.

MINDSET Integrated Co. And US Radiology Specialists, Inc. Announce Strategic Agreement On Brain Injury Assessment

Retrieved on: 
Tuesday, March 19, 2024
MRI, White matter, DTI, Quantify, Patient, Brain, TBI, Radiology, Motion, Doctor of Philosophy, Magnetic resonance imaging, Google Images, Traumatic brain injury, Medical imaging

ALBUQUERQUE, N.M. and RALEIGH, N.C., March 19, 2024 /PRNewswire-PRWeb/ -- US Radiology Specialists Inc. (US Radiology) and MINDSET Integrated Co. (MINDSET®) today announced an expanded strategic distribution agreement. This collaboration will significantly increase access to MINDSET's quantitative volumetric magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) analysis software, Quantify®, across the US Radiology network.

Key Points: 
  • Cutting-edge quantitative volumetric and DTI analysis solution for brain injury expands to the US Radiology network of over 180 patient imaging sites.
  • ALBUQUERQUE, N.M. and RALEIGH, N.C., March 19, 2024 /PRNewswire-PRWeb/ -- US Radiology Specialists Inc. (US Radiology) and MINDSET Integrated Co. (MINDSET®) today announced an expanded strategic distribution agreement.
  • "We believe MINDSET's Quantify reporting allows us to provide the most comprehensive clinical information pertaining to traumatic brain injury.
  • Additionally, more sites across US Radiology are scheduled to come online in the coming months, further expanding the company's reach and capabilities.

Philips teams with SyntheticMR to deliver breakthrough AI-based quantitative brain imaging in MR to advance neurology care for patients

Retrieved on: 
Friday, March 1, 2024
MRI, Acquisition, CE, White matter, Myenteric plexus, 2D, AI, Traumatic brain injury, Magnetic resonance imaging, FDA, Synthetic, Cerebrospinal fluid, 3D, Neurodegenerative disease, TBI, Radiology, Multiple sclerosis, DSM-IV codes, PHG, Quant, Health, Patient, Dementia, Diagnosis, Software, AEX, Brain, Medical imaging

As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare.

Key Points: 
  • As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare.
  • Philips' exclusive agreement with SyntheticMR makes it the only company currently able to offer SyMRI NEURO 3D capability on MR scanners.
  • Accurate measurement of the volume and distribution of different tissue types in the brain is important for diagnosing brain disease.
  • "Smart Quant allows for shorter exams and exploration of quantitative metrics, which show great potential to better stratify patients with similar imaging characteristics on conventional MR sequences.

INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024

Retrieved on: 
Tuesday, February 6, 2024
TNF, Science, Axon, MD, MCI, Neurology, CFS, Acquisition, White matter, University of Florida, Doctor of Philosophy, University, Webcast, NFL, Pharmaceutical industry

Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XProTM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, announces its management will be participating in Baird’s Biotech Discovery Series webcast on Tuesday, February 13, 2024 at 10:30AM EST.

Key Points: 
  • Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XProTM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, announces its management will be participating in Baird’s Biotech Discovery Series webcast on Tuesday, February 13, 2024 at 10:30AM EST.
  • The speakers will cover two key topics – first, they will provide an update on the unique features of the Company’s  ongoing blinded, randomized, placebo-controlled Phase II trial for Early Alzheimer's disease (MCI/Mild AD).
  • Baird’s Biotech Discovery Series, which launched in early 2022, is an opportunity for investors to hear directly from interesting and innovative public and private biotech companies in a fireside chat format.
  • We invite key members of management and frequently ask related third parties to join the discussion to learn why they are excited about the science and opportunity for these emerging biotech leaders.

Cognito Therapeutics Announces First Patient Enrolled in HOPE Biomarker Study

Retrieved on: 
Tuesday, January 23, 2024
Hardware, FDA, Data Management, Other Health, Technology, Pharmaceutical, Mental Health, Medical Devices, Clinical Trials, Science, Biotechnology, Software, Other Science, Health, Research, Patient, HOPE, Therapy, MRI, ARIA, EEG, Failure, Atrophy, Disease, Plasma, Journal, Alzheimer's disease, Safety, Cognition, Biomarker, Cerebrospinal fluid, White matter, Brain, Medical imaging

Cognito Therapeutics , a neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, announced today the first patient enrolled in a biomarker substudy within the HOPE pivotal trial .

Key Points: 
  • Cognito Therapeutics , a neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, announced today the first patient enrolled in a biomarker substudy within the HOPE pivotal trial .
  • “The enrollment of the first patient in the HOPE biomarker substudy is a clinical milestone for our company.
  • We are on track to achieve study completion within our projected timelines, with over 240 patients currently enrolled in the HOPE study across 60 active sites across the US,” said Ralph Kern, M.D., MHSc, Chief Medical Officer, Cognito Therapeutics.
  • "We are well-positioned to achieve our study timeline goals, as we advance towards potential approval of the first non-pharmacologic disease-modifying therapy for Alzheimer’s Disease."

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease

Retrieved on: 
Monday, November 27, 2023
Phase, Patient, Alzheimer's disease, MRI, Sécurité, EMA, White matter, Brain, Inflammation, Medication, ANSM, Authorization, Biomarker, CTA, AEMPS, Pharmaceutical industry

This authorization follows the acceptance of the Company’s Clinical Trial Application (CTA) under EU Clinical Trials Regulation and prior EMA's Authorized Decision in Poland on Nov 15, 2023.

Key Points: 
  • This authorization follows the acceptance of the Company’s Clinical Trial Application (CTA) under EU Clinical Trials Regulation and prior EMA's Authorized Decision in Poland on Nov 15, 2023.
  • The Spanish and French arms are part of the Company’s international clinical development strategy for XPro™ in patients with early AD.
  • We believe clinical sites in these two countries will be significant contributors to the Phase II program and will be part of the global Phase III clinical trial,” said RJ Tesi M.D., CEO of INmune Bio.
  • The Phase II clinical trial is a global, multi-center, randomized clinical study in patients diagnosed with early Alzheimer's disease who have biomarkers of elevated inflammation.

Studies: Promising Cognitive and Imaging Results in Alzheimer’s and pre-dementia Patients

Retrieved on: 
Tuesday, November 21, 2023
Quality of life, Clutch (eggs), Cognition, Dementia, Attention, Medicine, Grammatical mood, Diet, White matter, Systems biology, Incidence, SAN, Recode, JAD, University, San Francisco Bay Area, Medicare, Worldwide, Bangladesh Technical Education Board, Patient, Memory, Curriculum, Journal, Hearing, Exercise

Overall, the researchers saw significant and widespread improvement in cognitive performance as measured by MoCA scores, which improved in 76% of patients and CNS-Vital Signs scores, which improved in 84% of patients.

Key Points: 
  • Overall, the researchers saw significant and widespread improvement in cognitive performance as measured by MoCA scores, which improved in 76% of patients and CNS-Vital Signs scores, which improved in 84% of patients.
  • They also saw physical brain improvements in the imaging results that showed a trend toward renormalization to results typically seen in healthy older adults.
  • While the imaging results appear to correspond with the cognitive assessment results, due to the small sample size and correction for multiple comparisons, the imaging results were not significant.
  • “These are promising and exciting results,” said Dr. Henry Mahncke , CEO of Posit Science.

“Defy Dementia with Sound.” Pixie Dust Technologies, Shionogi and Shionogi Healthcare create Gamma Wave Sound to boost everyday cognitive care.

Retrieved on: 
Wednesday, December 20, 2023
Other Health, Seniors, Audio, Video, Other Technology, Research, TV and Radio, Software, Mental Health, Music, Medical Devices, Consumer, Science, Technology, Entertainment, Online, Health, Apps, Applications, Health Technology, Patient, Sound, Quality of life, Dementia, Multimedia, White matter, Patent, Brain, Atrophy, Shionogi, Medical imaging

The Dementia Care Project by Gamma Wave Sound is an initiative designed to help people care for their cognitive function through auditory stimulation.

Key Points: 
  • The Dementia Care Project by Gamma Wave Sound is an initiative designed to help people care for their cognitive function through auditory stimulation.
  • Turning gamma waves technology into a readily available audio experience presents new possibilities in providing cognitive stimulation for dementia.
  • Six major companies across industries in Japan have come together to form the alliance to boost dementia care as part of the Dementia Care Project by Gamma Wave Sound.
  • Furthermore, music artists who support the initiative have released the Gamma Wave Sound edit of their tracks, accelerating the efforts to deliver Gamma Wave Sound through entertainment.

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe

Retrieved on: 
Wednesday, November 15, 2023
Brain, Research, D, Clinical trial, Patient, White matter, Alzheimer's disease, Phase, MRI, Biomarker, CTA, Inflammation, Health insurance

Boca Raton, Florida, Nov. 15, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company dedicated to  advancing treatments that leverage the patient’s innate immune system to combat disease, has received acceptance of a Clinical Trial Application (CTA) under EU Clinical Trials Regulation to initiate a Phase II trial in Early Alzheimer’s Disease (AD) with XPro™ in Poland. Additional regulatory approval for the Phase II AD clinical trial is expected from at least two to potentially six more EU countries in the upcoming months.  The EU approval is part of the Company’s international clinical development strategy for XPro™ in patients with early AD. The trial is currently enrolling patients in Australia, Canada, and the United Kingdom.

Key Points: 
  • Additional regulatory approval for the Phase II AD clinical trial is expected from at least two to potentially six more EU countries in the upcoming months.
  • The EU approval is part of the Company’s international clinical development strategy for XPro™ in patients with early AD.
  • The Phase II clinical trial is a global, multi-center, randomized clinical study in patients diagnosed with early Alzheimer's disease who have biomarkers of elevated inflammation.
  • In a prior Phase I open-label trial, INmune Bio met all primary and secondary endpoints.

Cognito Therapeutics Phase 2 OVERTURE Study MRI Imaging Analysis Published in Journal of Alzheimer’s Disease

Retrieved on: 
Monday, December 11, 2023
Technology, Medical Devices, Neurology, Science, Consumer, Clinical Trials, Biotechnology, Health, Other Science, Research, Other Technology, Software, Other Health, Hardware, Pharmaceutical, Data Management, Seniors, Axon, Therapy, Alzheimer's disease, HOPE, White, Hippocampus, Disease, Clinical trial, Journal of Alzheimer's Disease, Learning, White matter, Patient, Journal, FDA, Atrophy, Memory, MRI, Cognito, HIV disease progression rates, Medical imaging

Cognito Therapeutics , a neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, announced today publication of MRI imaging data from its Phase 2 OVERTURE study in the Journal of Alzheimer’s Disease .

Key Points: 
  • Cognito Therapeutics , a neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, announced today publication of MRI imaging data from its Phase 2 OVERTURE study in the Journal of Alzheimer’s Disease .
  • White matter volume assessments were performed using T1-weighted MRI, and myelin content assessments were performed using T1-weighted/T2-weighted MRI ratios.
  • “Our Phase 2 OVERTURE study imaging results published in the Journal of Alzheimer's Disease, show that our proprietary gamma sensory stimulation reduced white matter atrophy and preserved brain myelin content in patients.
  • The Company’s lead therapy is currently in a pivotal study (HOPE) in Alzheimer’s Disease and was awarded FDA Breakthrough Device Designation.